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own medical students for the case discus-
sion sessions. This type of initiative builds
on clinical pharmacology and therapeutics
programs in the US that have developed
effective core curricula1,4; on work describ-
ing what types of educational interventions
can improve prescribing by medical student
and junior doctors8; and by national initia-
tives to make online learning modules
developed by national experts available to
students in multiple medical schools across
a country.9
This pilot program is supported by the
ASCPT; generously funded by the
PhRMA Foundation; and enabled by the
cooperation of the faculty at the NIH who
offer their current clinical pharmacology
course for research fellows. If this first
installment of six modules proves success-
ful, it can easily be expanded by the crea-
tion of a second group of six modules,
perhaps featuring learning modules about
drug allergies, the process of new drug dis-
covery and development, and other impor-
tant topics that are not available from such
expert faculty to most of our students at
US medical schools.
We are excited by this collaboration
between the ASCPT, the NIH, the FNIH,
the Reagan-Udall Foundation, and the
PhRMA Foundation, and we hope that as
these modules become available, many
medical schools in the US (and possibly
other institutions such as schools of phar-
macy, schools for nurse practitioners, or
schools for physicians’ assistants) will
choose to take advantage of them locally.
Most US medical schools do not have a
critical mass of faculty trained in these vari-
ous aspects of clinical pharmacology and
therapeutics to offer such high-quality ses-
sions, and perhaps the availability of such
free online learning resources will help us
prepare all of our medical students in the
US to be effective and safe prescribers on
their first days of internship.
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Failures in trials for Alzheimer’s disease (AD) may be attributable
to inadequate dosing, population selection, drug inefficacy, or
insufficient design optimization. The Coalition Against Major
Diseases (CAMD) was formed in 2008 to develop drug
development tools (DDT) to expedite drug development for AD
and Parkinson’s disease.1 CAMD led a process that successfully
advanced a clinical trial simulation (CTS) tool for AD through the
formal regulatory review process at the US Food and Drug
Administration (FDA) and European Medicines Agency (EMA).
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THE PROCESS OF MODEL
DEVELOPMENT
A clinical trial simulation (CTS) tool was
developed to describe disease progression
based on longitudinal Alzheimer’s Disease
Assessment Scale-Cognitive sub-scale
(ADAS-Cog) scores in mild-to-moderate
AD, in a three-stage approach: (1) con-
struction of a standardized database, (2)
model development and evaluation, (3)
FDA/EMA review for endorsement.
To capture the maximum amount of
information available for development of
the CTS tool, data from a variety of sources
were needed, requiring a model that simul-
taneously fitted summary and patient-level
data. The CAMD database consists of
patient-level, control-arm clinical trial data
(both on stable background therapy and
placebo only) from CAMD members. A
total of 3,179 patients from the CAMD
database were used for model development
and evaluation. Demographics, genetics,
and individual items from cognitive scales
(MMSE, ADAS-Cog, etc.) were included.
Biomarker data were not consistently col-
lected by industry sponsors; making their
integration into the CTS tool difficult.
The CTS tool has three basic compo-
nents that model drug, disease, and clinical
trial features. The CAMD database
enabled modeling of the placebo effect as
well as the changing probability of a
patient dropping out of a trial over time. To
model the natural history of the disease,
data were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI)
database (http://adni.loni.usc.edu); launched
in 2003 by the National Institute on Aging
(NIA), the National Institute of Biomedi-
cal Imaging and Bioengineering (NIBIB),
the FDA, private pharmaceutical compa-
nies, and nonprofit organizations, as a $60
million, 5-year public–private partnership.
ADNI’s primary goal has been to evaluate
how to combine data from magnetic reso-
nance imaging (MRI), positron emission
tomography (PET), other biological
markers, and clinical and neuropsychologi-
cal assessments to measure the progression
of mild cognitive impairment (MCI) and
early Alzheimer’s disease (AD).
Modeling the drug effect was more chal-
lenging, given the lack of active treatment
arm data in the CAMD database. There-
fore, summary-level data from the literature
were used; specifically, from 73 publica-
tions of unique trials that represented over
19,972 patients and 84,000 individual
observations. However, because these trials
pertain to drugs approved only for sympto-
matic effects (i.e., the cholinesterase inhibi-
tors and memantine), the team reached
consensus with the FDA on a modeling
approach that would account for potential
disease modification even in the absence of
actual data from a drug that has been
shown to be disease-modifying.
Disease progression is conceptualized as
the longitudinal change in ADAS-Cog
over time.2 ADAS-Cog scores, bounded
between 0 and 70, progress over time
according to a sigmoid curve.3,4 This curve
is well approximated by the logit transfor-
mation of a linear time course, the latter
being defined by an intercept (baseline)
and a slope (disease progression) over time.
A Bateman function describes the placebo
effect as a temporary beneficial change that
eventually disappears, returning to the pro-
gression state and rate that would be
expected under natural progression.5,6 The
pattern associated with presumed “purely
symptomatic” effects has so far been
described as an overall function shift
(intercept change with equal slope), such
that the apparent rate of progression may
change temporarily, but returns to the nat-
ural progression rate after some relatively
short duration.3–5 By contrast, it has been
generally hypothesized that the pattern
associated with a “disease-modifying effect”
would manifest as a change (slowing) of
the progression rate (slope), consistent
with a benefit that continues to accrue
over some relatively long duration.3,5
The FDA and EMA agreed to this con-
ceptualization, recognizing that, for a
disease-modifying claim, changing the rate
of progression needs to be tied to a bio-
marker change reflecting underlying patho-
physiology, as expressed in a recent FDA
draft guidance.6
CLINICAL TRIAL SIMULATION TOOL
This CTS tool incorporates covariates that
may affect disease progression, such as age,
gender, and APOE4 status. APOE4 car-
riers showed a faster rate of progression
than noncarriers,2 providing a quantitative
estimate supporting current thinking about
risk factors, with younger patients progress-
ing faster. The model components provide
a platform that enables simulation of a wide
range of clinical trials according to varia-
tions in (1) drug, (2) disease state, and (3)
trial design to select a trial design with a
high likelihood of detecting a treatment
effect as well as to evaluate the trade-off
between sample size and power. The techni-
cal and scientific intricacies of the CTS tool
are described in more detail elsewhere.2
The CTS tool’s flexibility to simulate
beyond the standard parallel design used in
most phase II and III AD clinical trials is




For simulation purposes, AChEi-like
effects (i.e., donepezil) can be considered as
having a mean (placebo-adjusted) change
in ADAS-Cog score of 2.5 points at 24
weeks (Edrug,24week 5 2.5), an ET50 (time
to reach 50% of Emax) of 1.62 weeks,2 and
an effect-offset half-life (after discontinua-
tion of treatment) of 1 week. Figure 1
(A-1 and A-2) displays the average simu-
lated results for a 6-week cross-over and a
12-week parallel design with a pure symp-
tomatic drug. Under these assumptions,
the treatment effect in the cross-over
design (placebo and treatment difference)
is period-independent. Thus, in this con-
text, a cross-over design may potentially
reduce sample size with appropriate power.
Table 1 summarizes the power and bias
for a 6-week cross-over study and a 12-week
parallel design study with a pure symptomatic
drug. Approximately 89% power was
achieved with 30 patients per arm (60
patients in total) in a 6-week cross-over study.
The power of a 12-week parallel design with
75 patients per arm (150 patients in total)
was approximately 82%. Meanwhile, as
expected, the relative bias (with respect to the
true mean differences at 24 week) of the 6-
week treatment in the cross-over study
(217.3%) was higher than the 12-week paral-
lel study (27.3%), both of which would
underestimate effects at week 24, given the
achievement of a partial drug effect over the
duration of the study. As shown in Table 1,
with a slower drug onset (e.g., ET50 of 3
weeks, two times that of donepezil); the
power in a 6-week cross-over study (81%)
remained comparable to a 12-week parallel
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study (79%), although the difference of the
relative bias for 6-week cross-over study signif-
icantly increased. Depending on the primary
goal of the study, a trade-off can be deter-
mined for the increase in bias and the gain in
power. For example, when the objective is to
test if the drug has any effect rather than to
measure the steady state treatment effect, the
cross-over design would be favorable due to
smaller sample size and higher power.
DISEASE-MODIFYING DRUG EFFECT
SCENARIOS
To test disease-modifying effects, 18-month,
randomized, parallel, placebo-controlled trials
have been often selected. The delayed-start
Figure 1 Simulation and power calculation for various study designs. (A) Simulated 6-week cross-over trials (A-1) vs. 12-week parallel trials (A-2) for
drugs with only symptomatic effects. (B) Simulated 78-week parallel trials (B-1) vs. 91-week delayed start trials (B-2) for a disease-modifying drug with
50% decrease on rate of disease progression. (C) Power curve of a 78-week parallel study design and a 91-week delayed start design by assumption of
different magnitude of effect (focused on disease modification). ADAScog, Alzheimer’s Disease Assessment Scale-Cognitive subscale.
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design may provide some empirical support
for disease modifying claims.7 The
following simulation compares both designs
(with N ranging from 100 to 600 patients
per group) for disease-modifying drugs
assumed to slow disease progression by 20%–
50%. Figure 1 (B-1 and B-2) displays the
average simulated results for a drug with
moderate disease-modifying effect (50%
disease-progression rate reduction, without
symptomatic effect) in a 78-week (18-month)
parallel trial vs. a 91-week delayed-start trial.
For an 18-month parallel design, approxi-
mately 85% power was achieved with 600
and 400 patients per group for 40% and
50% effects on progression, respectively
(Figure 1C). Power to reject both hypothe-
ses in the delayed-start design was lower
(Figure 1C). For a moderate disease-
modifying effect of 50% progression rate
reduction, 600 patients achieve an approxi-
mate 75% power, although the delayed-start
design could potentially provide additional
inference for disease-modifying effects.
These results demonstrate CTS could
help development teams better understand
and compare the operating characteristics
of a wide range of trial design options for
cognition as a primary endpoint in mild-
to-moderate AD. This resource allows
selecting designs tailored to particular
assumptions and considerations about the
drug effects mechanism, magnitude, onset,
and offset, within the trial’s objectives.
Such quantitative methodology permits a
comprehensive integration of relevant
information available for decision-making.
REGULATORY DECISIONS
After submitting briefing packages to the
FDA and EMA, and holding face-to-face
meetings with both agencies, the FDA
deemed the CTS tool scientifically sup-
ported and fit for purpose to aid in the
design of future clinical trials in patients
with mild to moderate AD on June 12,
2013. EMA considered that the model is
“suitable for qualification for use in drug
development as a longitudinal model for
describing changes in cognition in patients
with mild-to-moderate AD; for use in trial
designs in mild-to-moderate AD; and for
use in assisting in trial designs in mild-to-
moderate AD, as defined by the context of
use” on 12 July 2013.8,9
The CAMD CTS tool for mild-to-
moderate AD patients is a prime example of
integration of patient-level and literature-
level data and the first to undergo a regula-
tory path for any disease. CTS tools are con-
tinuously evolving, and predictive accuracy
needs to be validated using a wide variety of
data sets. It is envisioned that this tool will
be adopted by sponsors in AD, and that
data will be shared so that the model can be
enriched and expanded with biomarker data.
Furthermore, given the awareness that treat-
ment of early stage disease seems critical to
achieve success, adapting and refining the
model with data on predementia will enable
sponsors to more accurately estimate clinical
trial design in mild cognitive impairment
and presymptomatic populations. This is of
special interest in light of the need for appro-
priate outcome measures for predementia
stages. The critical success factor for such
future investments requires sharing of clini-
cal trial data in these stages. As information
accrues regarding optimal endpoints for dif-
ferent populations, including biomarkers
and cognitive assessments, the quantitative
approach applied in the development of the
CTS tool will be instrumental in building
next-generation modeling and simulation
tools.
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